Cardinal Health, Inc. (NYSE:CAH) shares rose more than 11% since the company’s reported Q4 results last week, with revenue of $47.1 billion coming in better than the Street estimate of $44.75 billion. Quarterly EPS was $1.05, missing the Street estimate of $1.17.

For the full 2023-year, the company expects EPS to be in the range of $5.05-$5.40, compared to the Street estimate of $5.37.

Analysts at Deutsche Bank raised their price target on the company’s shares to $69 from $51 following the earnings announcement. According to the analysts, the core pharmaceutical segment outperformed expectations, delivering better than expected revenue (up 13%), operating earnings (up 26%) and margin of 1.04%.

The analysts think the Medical segment continues to be the trouble spot for the company, being plagued by demand volatility, inflationary pressures, rising transportation costs, and the optics of the divestiture of the Cordis business.